IntraBio's Levacetylleucine Shows Promise in A-T Phase III Trial
Event summary
- IntraBio's Phase III trial of levacetylleucine for Ataxia-Telangiectasia (A-T) met primary endpoint, showing statistically significant improvement in neurological symptoms.
- Treatment with levacetylleucine resulted in a mean change in SARA score of -1.92 compared with -0.14 for placebo (p<0.001).
- The study was published in The Lancet Neurology on June 18, 2026.
- A supplementary New Drug Application (sNDA) for levacetylleucine is under review by the FDA with a PDUFA date of September 19, 2026.
- A variation application has been submitted to the European Medicines Agency to expand the approved marketing authorization for levacetylleucine to include A-T.
The big picture
IntraBio's positive Phase III data for levacetylleucine positions it as a potential first-in-class therapy for A-T, a rare and progressive neurological disease with no current FDA-approved treatments. The publication in The Lancet Neurology lends credibility to the findings, while the pending regulatory decisions will determine the near-term commercial prospects. The success of levacetylleucine could also set a precedent for developing therapies for other rare neurological disorders.
What we're watching
- Regulatory Approval
- Whether the FDA and EMA will approve levacetylleucine for A-T by their respective deadlines, given the positive Phase III data.
- Commercialization Strategy
- How IntraBio plans to commercialize levacetylleucine if approved, considering the rare disease space and potential pricing dynamics.
- Competitive Landscape
- The pace at which IntraBio can establish levacetylleucine as a standard of care for A-T, given the lack of current FDA-approved therapies.